All In Biotech

Drug Trial Radar · NCT03127514

AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS

Last checked: Nov 19, 2026Latest source record: May 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 137 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

137

Actual

Start

Jun 22, 2017

Primary completion

Sep 25, 2019

Study completion Nov 24, 2019

Sponsor

Lead sponsor
Amylyx Pharmaceuticals Inc.Industry
Sponsor type
Industry
Collaborators
ALS Finding a Cure; ALS Association; Northeast ALS Consortium; Neurological Clinical Research Institute at Massachusetts General Hospital; Leandro P. Rizzuto Foundation
First posted
Apr 25, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The CENTAUR trial was a 2:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and efficacy of AMX0035 for the treatment of ALS.

Conditions

  • Amyotrophic Lateral Sclerosis
  • Motor Neuron Disease
  • Neuromuscular Diseases
  • Neurodegenerative Diseases
  • Spinal Cord Diseases
  • TDP-43 Proteinopathies
  • Nervous System Diseases
  • Central Nervous System Diseases

Interventions

  • AMX0035Drug

    AMX0035

  • PlaceboOther

    Matching Placebo Comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Slope ChangeTime frame: 24 Weeks
  2. Number of Participants With Adverse EventsTime frame: 24 Weeks
  3. Number of Participants in Each Group Able to Remain on Study Drug Until Planned DiscontinuationTime frame: 24 weeks

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Barrow Neurological Institute

    Phoenix, Arizona

  • UC Irvine Medical Center

    Orange, California

  • Forbes Norris MDA/ALS Research Center - California Pacific Medical Center

    San Francisco, California

  • University of Florida Medical Center

    Gainesville, Florida

  • Carol and Frank Morsini Center for Advanced Health Care - University of South Florida

    Tampa, Florida

  • Emory University Hospital

    Atlanta, Georgia

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • University of Kentucky Medical Center

    Lexington, Kentucky

  • Ochsner Neuroscience Institute

    New Orleans, Louisiana

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Massachusetts Memorial Medical Center

    Worcester, Massachusetts

  • University of Michigan Medical Center

    Ann Arbor, Michigan

  • Hennepin County Medical Center

    Minneapolis, Minnesota

  • Washington University Medical Center

    St Louis, Missouri

  • Neurology Associates P.C.

    Lincoln, Nebraska

  • Mount Sinai Beth Israel

    New York, New York

  • Wake Forest Baptist Medical Center

    Winston-Salem, North Carolina

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • The Penn Comprehensive ALS Center

    Philadelphia, Pennsylvania

  • Temple University Hospital

    Philadelphia, Pennsylvania

  • Texas Neurology, P.A.

    Dallas, Texas

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas

  • ALS Center at the Swedish Neuroscience Institute

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.